Congenital absence of norepinephrine due to CYB561 mutations

Objective Cytochrome b561 (CYB561) generates ascorbic acid, a cofactor in the enzymatic conversion of dopamine to norepinephrine by dopamine β-hydroxylase. We propose that the clinical relevance of this pathway can be revealed by characterizing the autonomic and biochemical characteristics of patients with CYB561 mutations. Methods We performed autonomic evaluations in 4 patients with lifelong orthostatic hypotension in whom CYB561 mutations were determined by genomic sequencing. Results Patients had disabling lifelong orthostatic hypotension (OH) and impaired blood pressure response to the Valsalva maneuver (VM), with exaggerated hypotension during phase 2 and lack of overshoot during phase 4. Heart rate ratios for sinus arrhythmia and the VM were normal. Plasma norepinephrine and metabolites were undetectable, and plasma dopamine and metabolites were normal. Droxidopa restored norepinephrine levels and improved OH. Patients 1 and 2 were sisters and homozygous for a nonsense mutation in exon 2, c.131G>A, p.Trp44 (Circ Res 2018). Their brother (patient 3) died at age 16 and his DNA was not available. Patient 4 was compound heterozygous; one allele had a missense mutation in exon 2, c157C>T, p.His.53Tyr, and the other had an exon 2 deletion. Conclusion CYB561 deficiency is characterized by selective sympathetic noradrenergic failure with lifelong, disabling OH but with normal sympathetic cholinergic (sweating) and parasympathetic (heart rate regulation) functions. We report a novel case of CYB561 deficiency due to an exon 2 deletion in one allele and a missense mutation in the other. These patients highlight the critical role CYB561 plays in sympathetic function and cardiovascular regulation.

[1]  M. P. van den Berg,et al.  Mutations in CYB561 Causing a Novel Orthostatic Hypotension Syndrome , 2018, Circulation research.

[2]  C. Nievergelt,et al.  Human heart rate: heritability of resting and stress values in twin pairs, and influence of genetic variation in the adrenergic pathway at a microribonucleic acid (microrna) motif in the 3'-UTR of cytochrome b561 [corrected]. , 2014, Journal of the American College of Cardiology.

[3]  L. Ghimire,et al.  Catecholamine pathway gene variation is associated with norepinephrine and epinephrine concentrations at rest and after exercise , 2012, Pharmacogenetics and genomics.

[4]  C. Mathias,et al.  Clinical, autonomic and therapeutic observations in two siblings with postural hypotension and sympathetic failure due to an inability to synthesize noradrenaline from dopamine because of a deficiency of dopamine beta hydroxylase. , 1990, The Quarterly journal of medicine.

[5]  I. Biaggioni,et al.  ENDOGENOUS RESTORATION OF NORADRENALINE BY PRECURSOR THERAPY IN DOPAMINE-BETA-HYDROXYLASE DEFICIENCY , 1987, The Lancet.

[6]  F. Boomsma,et al.  EFFECT OF UNNATURAL NORADRENALINE PRECURSOR ON SYMPATHETIC CONTROL AND ORTHOSTATIC HYPOTENSION IN DOPAMINE-BETA-HYDROXYLASE DEFICIENCY , 1987, The Lancet.

[7]  M. Grant,et al.  Elevated levels of plasma prorenin (inactive renin) in diabetic and nondiabetic patients with autonomic dysfunction. , 1987, The Journal of clinical endocrinology and metabolism.

[8]  F. Boomsma,et al.  CONGENITAL DOPAMINE-BETA-HYDROXYLASE DEFICIENCY A Novel Orthostatic Syndrome , 1987, The Lancet.

[9]  J. Onrot,et al.  Isolated failure of autonomic noradrenergic neurotransmission. Evidence for impaired beta-hydroxylation of dopamine. , 1986, The New England journal of medicine.

[10]  N. Abumrad,et al.  Hyperinsulinemia and Insulin Resistance in Dopamine &bgr;-Hydroxylase Deficiency , 2017, The Journal of clinical endocrinology and metabolism.